Антибиотична резистентност особено от грам-отрицателни бактерии почти създаде ситуация, подобна на криза. Новият антибиотик Zosurabalpin (RG6006) показва обещания. Установено е, че е ефективен срещу резистентни на лекарства, грам-отрицателни бактерии CRAB в предклинични проучвания.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of антибиотици to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of антибиотик резистентност.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available антибиотици. There is an urgent need for an effective антибиотик against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective антибиотик. A progress towards this goal has been reported.
Scientists have identified a novel class of антибиотици namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Зосурабалпин (RG6006) е антибиотик candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-клиничен trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame антибиотик-resistance mechanism of CARB suggesting зосурабалпин има потенциал.
Hence, human клиничен trials have been initiated to check for safety and efficacy зосурабалпин при лечение на инвазивни инфекции, причинени от CRAB.
***
Литература:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel антибиотик class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Хоузър С., и др 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Клиничен Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
